Paper39155331
In silico and experimental potentials of 6-shogaol and meglumine antimoniate on Leishmania major: multiple synergistic combinations through modulation of biological properties.
Shahsavari S and 5 others. Immunol Res, 2024. Cited by 6 papers, by iCite.
Cite this record
ConductScience Library. In silico and experimental potentials of 6-shogaol and meglumine antimoniate on Leishmania major: multiple synergistic combinations through modulation of biological properties. Papers, record 39155331. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39155331
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- In silico and experimental potentials of 6-shogaol and meglumine antimoniate on Leishmania major: multiple synergistic combinations through modulation of biological properties.
- PubMed
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Meglumine Antimoniate | Major topic |
| Nitric Oxide | Major topic |
| Nitric Oxide Synthase Type II | Major topic |
| Leishmania major | Major topic |
| Antiprotozoal Agents | Major topic |
| Catechols | Major topic |
| Drug Synergism | Major topic |
| Animals | |
| Mice | |
| Macrophages | |
| Apoptosis | |
| Antioxidants | |
| Molecular Docking Simulation | |
| Leishmaniasis, Cutaneous | |
| RAW 264.7 Cells | |
| Humans | |
| Meglumine | |
| Computer Simulation | |
| Organometallic Compounds |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 99001204 | Kerman University of Medical Sciences | PubMed |
Source PubMed
References35
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35106852 | A systematic review and meta-analysis of preclinical and clinical studies on the efficacy of ginger for the treatment of fatty liver disease. | Phytother Res | 2022 | https://conductscience.org/library/papers/35106852 | PubMed |
| 2 | 26829519 | In Vitro and In Vivo Antileishmanial Activities of Pistacia vera Essential Oil. | Planta Med | 2016 | https://conductscience.org/library/papers/26829519 | PubMed |
| 3 | 34890999 | Exploring the paradox of defense between host and Leishmania parasite. | Int Immunopharmacol | 2022 | https://conductscience.org/library/papers/34890999 | PubMed |
| 4 | 34648927 | The effects of medicinal herbs and marine natural products on wound healing of cutaneous leishmaniasis: A systematic review. | Microb Pathog | 2021 | https://conductscience.org/library/papers/34648927 | PubMed |
| 5 | 31736746 | Isobologram Analysis: A Comprehensive Review of Methodology and Current Research. | Front Pharmacol | 2019 | https://conductscience.org/library/papers/31736746 | PubMed |
| 6 | 16778319 | Current scenario of drug development for leishmaniasis. | Indian J Med Res | 2006 | https://conductscience.org/library/papers/16778319 | PubMed |
| 7 | 34648629 | ASSESSMENT OF THE OXIDATIVE AND NITROSATIVE STRESS IN THE SERUM OF SAUDI PATIENTS WITH CUTANEOUS LEISHMANIASIS BEFORE AND AFTER TREATMENT. | J Parasitol | 2021 | https://conductscience.org/library/papers/34648629 | PubMed |
| 8 | 34203813 | Benefits of Ginger and Its Constituent 6-Shogaol in Inhibiting Inflammatory Processes. | Pharmaceuticals (Basel) | 2021 | https://conductscience.org/library/papers/34203813 | PubMed |
| 9 | 17761485 | Artemisinin triggers induction of cell-cycle arrest and apoptosis in Leishmania donovani promastigotes. | J Med Microbiol | 2007 | https://conductscience.org/library/papers/17761485 | PubMed |
| 10 | 34688150 | In vitro and in vivo therapeutic potentials of 6-gingerol in combination with amphotericin B for treatment of Leishmania major infection: Powerful synergistic and multifunctional effects. | Int Immunopharmacol | 2021 | https://conductscience.org/library/papers/34688150 | PubMed |
| 11 | 33957562 | Host immune response against leishmaniasis and parasite persistence strategies: A review and assessment of recent research. | Biomed Pharmacother | 2021 | https://conductscience.org/library/papers/33957562 | PubMed |
| 12 | 35147170 | Orally consumed ginger and human health: an umbrella review. | Am J Clin Nutr | 2022 | https://conductscience.org/library/papers/35147170 | PubMed |
| 13 | 35472413 | In silico and in vitro antileishmanial effects of gamma-terpinene: Multifunctional modes of action. | Chem Biol Interact | 2022 | https://conductscience.org/library/papers/35472413 | PubMed |
| 14 | 31540192 | Key Topics in Molecular Docking for Drug Design. | Int J Mol Sci | 2019 | https://conductscience.org/library/papers/31540192 | PubMed |
| 15 | 30771740 | Host's immune response in unresponsive and responsive patients with anthroponotic cutaneous leishmaniasis treated by meglumine antimoniate: A case-control study of Th1 and Th2 pathways. | Int Immunopharmacol | 2019 | https://conductscience.org/library/papers/30771740 | PubMed |
| 16 | 32590317 | The potential role of nicotinamide on Leishmania tropica: An assessment of inhibitory effect, cytokines gene expression and arginase profiling. | Int Immunopharmacol | 2020 | https://conductscience.org/library/papers/32590317 | PubMed |
| 17 | 32931505 | The effects of solid-state fermentation on the content, composition and in vitro antioxidant activity of flavonoids from dandelion. | PLoS One | 2020 | https://conductscience.org/library/papers/32931505 | PubMed |
| 18 | 37682934 | In silico and in vitro potentials of crocin and amphotericin B on Leishmania major: Multiple synergistic mechanisms of actions. | PLoS One | 2023 | https://conductscience.org/library/papers/37682934 | PubMed |
| 19 | 33765083 | The antioxidant response favors Leishmania parasites survival, limits inflammation and reprograms the host cell metabolism. | PLoS Pathog | 2021 | https://conductscience.org/library/papers/33765083 | PubMed |
| 20 | 34664543 | Vaccines against leishmaniasis: using controlled human infection models to accelerate development. | Expert Rev Vaccines | 2021 | https://conductscience.org/library/papers/34664543 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42643551 | Effectiveness of harmaline along with meglumine antimoniate on Leishmania major. | Vet Res Forum | 2026 | https://conductscience.org/library/papers/42643551 | PubMed |
| 40589914 | An inclusive assessment of apoptosis mechanisms in Leishmania species: A narrative literature review. | Curr Res Parasitol Vector Borne Dis | 2025 | https://conductscience.org/library/papers/40589914 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39155331
GET https://conductscience.org/api/papers/v1/39155331/references?page=2